Clinical trial • Phase I • Oncology|Gastroenterology
Clinical trial in Locally advanced rectal cancer|Rectal cancer
Phase I trial for Locally advanced rectal cancer|Rectal cancer. None/Not specified-controlled. 23 participants.
Overview
- Trial Therapeutic Area
- Oncology|Gastroenterology
- Trial Disease
- Locally advanced rectal cancer|Rectal cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 21-11-2023
- First CTIS Authorization Date
- 18-03-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Netherlands.
- Comparator
- None/Not specified
- Target Sample Size
- 23
Eligibility
Recruits 23 No vulnerable population selected; consent/assent procedures not specified in available documents..
- Vulnerable Population
- No vulnerable population selected; consent/assent procedures not specified in available documents.
Recruitment
- Planned Sample Size
- 23
- Recruitment Window Months
- 17
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 23
Netherlands
- Earliest CTIS Part Ii Submission Date
- 07-03-2024
- Latest Decision Or Authorization Date
- 08-12-2025
- Processing Time Days
- 641
- Number Of Sites
- 1
- Number Of Participants
- 23
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Gastroenterology and Hepatology
- Principal Investigator Name
- Wouter. B. Nagengast
- Principal Investigator Email
- w.b.nagengast@umcg.nl
- Contact Person Name
- Wouter. B. Nagengast
- Contact Person Email
- w.b.nagengast@umcg.nl
- Number Of Participants
- 23
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- Girentuximab (labelled with Zirconium-89) for Gastroenteropancreatic neuroendocrine neoplasms|Hepatocellular carcinoma|Biliary tract cancer
- DOSTARLIMAB for Resectable colon cancer (pMMR/MSS)
- D,L-LYSINE ACETYLSALICYLATE for Metastatic colorectal cancer|Chemo-resistant metastatic colorectal cancer
- BEVACIZUMAB for Advanced hepatocellular carcinoma|Liver transplant recipient
- Capecitabine for Gastric adenocarcinoma|Gastroesophageal junction adenocarcinoma